PharmaPendium®
2019.02 Release

The content release includes the following updates

1. 4 New Drugs in PharmaPendium
   - Calaspargase Pegol
   - Gilteritinib Fumarate
   - Ravulizumab
   - Tagraxofusp

2. FDA Approval Documents
   - 345 new FDA Approval Documents
   - 7,109 new pages of FDA Approval Documents

3. The new totals for PharmaPendium are:
   - 2,554,308 pages of FDA Approval documents (Including FDA Classic Collection)
   - 116,939 documents of FDA Approval documents (Including FDA Classic Collection)
   - 4,578 drugs with data in PharmaPendium
   - 1,838,880 extracted safety data lines
   - 1,716,358 extracted PK data lines
   - 339,939 extracted ME data lines
   - 2,968,207 extracted Efficacy data lines
   - 128,749 extracted Activity data lines
   - 12,285,595 FAERS (post-marketing) reports
   - 12,814 documents / 234,765 pages of EMA Approval documents
   - 18,304 documents / 719,718 pages of FDA Advisory Committees Meetings documents
   - 10,906 documents / 308,149 pages of FDA Classic Collection
   - 2,769 documents / 32,290 pages of DESI documents

Copyright © 2019 Elsevier Life Sciences IP Limited. All rights reserved. PharmaPendium is a trade mark of Elsevier Life Sciences IP Limited. RELX Group and the RE symbol are trade marks of RELX Group plc, used under license.

January 2019